Paul Hudson is more confident in Sanofi's ability to produce a Covid-19 vaccine — report

Sanofi CEO Paul Hudson expressed renewed confidence Friday regarding its company’s Covid-19 vaccine candidate being developed with GSK.

As the candidate is set to start clinical trials sometime next month, Hudson told Reuters that Sanofi has seen positive data so far this summer. That gusto builds upon comments he made in June about the higher likelihood Sanofi produces a vaccine with greater than 70% efficacy compared to rivals.